Sunshine Biopharma Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 15, 2019 and accepted by EDGAR at Aug 15, 2019, 13:29 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $3.0k | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $3.2k | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $1.5k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $1.6k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $1.6k | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $1.7k | us-gaap:GrossProfit |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$66.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$188.4k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $18.3k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $64.6k | us-gaap:InterestExpense |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$710.9k | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$913.4k | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$280.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $485 | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2019-06-30 | $37.3k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $70.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $109.4k | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $925.7k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $925.7k | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | −$816.3k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001654954-19-009672. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.